ArticleNature communications2026
Engineered VPg saRNA achieves cap-independent, low-immunogenic and precise encoding of therapeutic proteins in vivo.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapy · 2026Review
- Therapeutic cancer vaccines: development, challenges, and future perspectives.Acta pharmacologica Sinica · 2026Review
- Engineered VPg saRNA achieves cap-independent, low-immunogenic and precise encoding of therapeutic proteins in vivo.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Self-amplifying mRNA (saRNA) vectors hold promise for the sustained expression of mRNA vaccines in vivo. However, their inherently high immunogenicity and low-fidelity replication-stemming from the RNA viral genome's replication mechanisms-limit their efficacy as replacements or adjuncts to protein therapies. Here we report an engineered viral protein genome-linked (VPg) saRNA vector derived from a Norovirus replicon, designed for rapid loading of therapeutic protein mRNAs in vitro. The engineered VPg saRNA is adapted for a range of therapeutic scenarios, including treatment of tumor-associated cachexia under conditions of translational restriction in cap-dependent metabolism, precise encoding of oncolytic mRNAs in vivo to achieve complex functionality, and therapy for graft-versus-host disease in highly auto-immune environments. VPg saRNA addresses key limitations of linear mRNA and conventional saRNA therapies, broadening the potential applications of mRNA-based treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.